Ernexa Therapeutics Inc. (ERNA)
| Market Cap | 7.46M -30.0% |
| Revenue (ttm) | n/a |
| Net Income | -12.27M |
| EPS | -18.60 |
| Shares Out | 1.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,227 |
| Open | 4.760 |
| Previous Close | 4.735 |
| Day's Range | 4.560 - 4.990 |
| 52-Week Range | 3.183 - 71.498 |
| Beta | 2.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About ERNA
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutic... [Read more]
Financial Performance
Financial StatementsNews
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available here
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System
Ernexa Therapeutics announces new ERNA-101 preclinical data
Ernexa Therapeutics (ERNA) announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition....
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 202...
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology Discussion explores challenges of immunolo...
Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3
Ernexa Therapeutics (ERNA) announced progress in the development of ERNA-101, the company’s therapeutic candidate, achieving multiple milestones that position the program for a planned investigational...
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company Company remains on track for anticipated IND filing...
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape
Ernexa Therapeutics initiated with a Buy at Brookline
Brookline initiated coverage of Ernexa Therapeutics (ERNA) with a Buy rating and $30 price target Ernexa is engineering induced pluripotent stem cells and transforming them into induced mesenchymal st...
3 Penny Stocks to Watch Now, 5/7/26
Ernexa Therapeutics ($ERNA), Powell Max Limited ($PMAX), and Ambitions Enterprise Management Co. ($AHMA) are the three penny stocks to watch on May 7, according to TipRanks’ Penny Stock Screener tool.
Ernexa Therapeutics announces new ERNA-101 preclinical data
Ernexa Therapeutics (ERNA) announced new preclinical data demonstrating that its lead cell therapy candidate, ERNA-101, in combination with PD-1 blockade, drives complete tumor clearance and 100% long...
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease...
Ernexa Therapeutics announces 1-for-25 reverse stock split
Ernexa Therapeutics announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share, at a ratio of 1-for-25, effective May 4 at…
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disea...
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer
Ernexa Therapeutics files $50M mixed securities shelf
06:51 EDT Ernexa Therapeutics (ERNA) files $50M mixed securities shelf
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET
Ernexa Therapeutics prices 21M shares at 50c in public offering
Ernexa Therapeutics (ERNA) announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock and warrants to purchase up to 21,000,000 shares of common stock,...
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of adva...
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
Access the “What This Means” segment here